Evidence map›Paper›PMID 25340823›Full record

ArticlePloS one2014

Comparative immune phenotypic analysis of cutaneous Squamous Cell Carcinoma and Intraepidermal Carcinoma in immune-competent individuals: proportional representation of CD8+ T-cells but not FoxP3+ Regulatory T-cells is associated with disease stage.

Andrew Freeman, Jennifer A Bridge, Pirashanthini Maruthayanar, Nana H Overgaard, Ji-Won Jung, Fiona Simpson, Tarl W Prow, H Peter Soyer, Ian H Frazer, Michael Freeman and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05377905 (Phase Ib/II Study of Micro-needle Array Containing Doxorubicin in Immune Competent or Immune-suppressed Patients With Cutaneous Squamous Cell Carcinoma), which is not on this map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05377905 phase1 / phase2recruitingnot on this mapstarted 2023, after this paper: background citation

Phase Ib/II Study of Micro-needle Array Containing Doxorubicin in Immune Competent or Immune-suppressed Patients With Cutaneous Squamous Cell Carcinoma

TypeinterventionalSponsorFalo, Louis, MDRan2023 to 2027Enrolled48ConditionsCutaneous Squamous Cell Carcinoma, Skin Cancers - Squamous Cell CarcinomaArmsMicroneedle Array Doxorubicin (MNA-D)
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Exhaustion of CD8Frontiers in immunology · 2023
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. The Tumor Microenvironment in SCC: Mechanisms and Therapeutic Opportunities.Frontiers in cell and developmental biology · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Andrew FreemanThe Skin Centre, Pindara Private Hospital, Gold Coast, Australia; Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Australia.
Jennifer A BridgeThe University of Queensland Diamantina Institute, University of Queensland, Translational Research Institute, Brisbane, Australia.
Pirashanthini MaruthayanarThe University of Queensland Diamantina Institute, University of Queensland, Translational Research Institute, Brisbane, Australia.
Nana H OvergaardThe University of Queensland Diamantina Institute, University of Queensland, Translational Research Institute, Brisbane, Australia.
Ji-Won JungThe University of Queensland Diamantina Institute, University of Queensland, Translational Research Institute, Brisbane, Australia.
Fiona SimpsonThe University of Queensland Diamantina Institute, University of Queensland, Translational Research Institute, Brisbane, Australia.
Tarl W ProwDermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Australia.
H Peter SoyerDermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Australia.
Ian H FrazerThe University of Queensland Diamantina Institute, University of Queensland, Translational Research Institute, Brisbane, Australia.
Michael FreemanThe Skin Centre, Pindara Private Hospital, Gold Coast, Australia; Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Australia.
James W WellsThe University of Queensland Diamantina Institute, University of Queensland, Translational Research Institute, Brisbane, Australia.
Translational Research Institute · AUUniversity of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Squamous Cell Carcinoma (SCC) is a type of non-melanoma skin cancer prevalent in immune-suppressed transplant recipients and older individuals with a history of chronic sun-exposure. SCC itself is believed to be a late-stage manifestation that can develop from premalignant lesions including Intraepidermal Carcinoma (IEC). Notably, while SCC regression is rare, IEC typically regresses in response to immune modifying topical treatments, however the underlying immunological reasons for these differential responses remain unclear. This study aimed to define whether IEC and SCC are associated with distinct immune profiles. We investigated the immune cell infiltrate of photo-damaged skin, IEC, and SCC tissue using 10-colour flow cytometry following fresh lesion digest. We found that IEC lesions contain higher percentages of CD3+ T-cells than photo-damaged skin, however, the abundance of CD3-CD56+ Natural Killer (NK) cells, CD11c+HLA-DR+ conventional Dendritic Cells (cDC), BDCA-2+HLA-DR+ plasmacytoid DC (pDC), FoxP3+ Regulatory T-cells (T-reg), Vα24+Vβ11+ invariant NKT-cells, and γδ Tcells did not alter with disease stage. Within the total T-cell population, high percentages of CD4+ T-cells were associated with SCC, yet CD8+ T-cells were less abundant in SCC compared with IEC. Our study demonstrates that while IEC lesions contain a higher proportion of T-cells than SCC lesions in general, SCC lesions specifically display a lower abundance of CD8+ T-cells than IEC. We propose that differences in CD8+ T-cell abundance contribute critically to the different capacity of SCC and IEC to regress in response to immune modifying topical treatments. Our study also suggests that a high ratio of CD4+ T-cells to CD8+ T-cells may be a immunological diagnostic indicator of late-stage SCC development in immune-competent patients.

Indexed as

AgedAged, 80 and overCarcinoma, Squamous CellCD11c AntigenCD3 ComplexCD56 AntigenCD8-Positive T-LymphocytesCell MovementDisease ProgressionFemaleForkhead Transcription FactorsHLA-DR AntigensHumansImmunophenotypingKiller Cells, NaturalMaleCD11c AntigenCD3 ComplexCD56 AntigenForkhead Transcription FactorsFOXP3 protein, humanHLA-DR AntigensNCAM1 protein, human

Identifiers

PMID25340823
PMCPMC4207854
OpenAlexW2052501998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.